Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer
出版年份 2016 全文链接
标题
Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 7, Pages 2159-2164
出版商
Baishideng Publishing Group Inc.
发表日期
2017-09-18
DOI
10.3748/wjg.v22.i7.2159
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- (2015) Ryan D. Cassaday et al. Clinical Lymphoma Myeloma & Leukemia
- Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)
- (2015) Veronika Malínková et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
- (2015) Zahi Mitri et al. INVESTIGATIONAL NEW DRUGS
- Pancreatic cancer: current management and treatment strategies
- (2015) Tamara M H Gall et al. POSTGRADUATE MEDICAL JOURNAL
- Chemotherapy for colorectal cancer in the elderly
- (2015) Jung Han Kim WORLD JOURNAL OF GASTROENTEROLOGY
- Transcriptional Control of Mitosis: Deregulation and Cancer
- (2015) Somsubhra Nath et al. Frontiers in Endocrinology
- Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present
- (2014) Mathew C Casimiro et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
- (2014) Gaëlle Mariaule et al. MOLECULES
- Management of colorectal cancer presenting with synchronous liver metastases
- (2014) Ajith K. Siriwardena et al. Nature Reviews Clinical Oncology
- A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
- (2014) E. R. Plimack et al. ONCOLOGIST
- Cyclin-dependent kinases as therapeutic targets in melanoma
- (2014) David M. Miller et al. Pigment Cell & Melanoma Research
- Role of surgery in colorectal cancer liver metastases
- (2014) Özgür Akgül WORLD JOURNAL OF GASTROENTEROLOGY
- PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis
- (2014) CHUNSHENG LI et al. Oncology Letters
- Highlights of the Latest Advances in Research on CDK Inhibitors
- (2014) Jonas Cicenas et al. Cancers
- Structural characterization of the cyclin-dependent protein kinase family
- (2013) Jane A. Endicott et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
- (2013) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
- (2013) Andrea Rocca et al. EXPERT OPINION ON PHARMACOTHERAPY
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
- (2012) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin
- (2012) Jong-Shiaw Jin et al. PATHOLOGY & ONCOLOGY RESEARCH
- Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
- (2012) M Orzáez et al. Cell Death & Disease
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
- (2011) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor
- (2010) Wei-Lien Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
- (2010) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
- (2010) D Bixby et al. LEUKEMIA
- Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
- (2009) D. S. Boss et al. ANNALS OF ONCOLOGY
- Cyclin-dependent kinases: a family portrait
- (2009) Marcos Malumbres et al. NATURE CELL BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started